Van 12 april tot en met 19 april vindt er onderhoud plaats aan de Radboud Repository. Het is mogelijk dat uw zoekactie incomplete resultaten oplevert. Indien u publicaties wilt uploaden kunt u dit doen via de Upload Full Text button. ****** From April 12th up to and including April 19th , the Radboud Repository will be undergoing maintenance. Please note that your search may produce incomplete results. If you would like to upload publications, you can do so by means of the Upload Full Text button.
In Vitro and In Vivo Characterization of an (18)F-AlF-Labeled PSMA Ligand for Imaging of PSMA-Expressing Xenografts
until further notice
SourceThe Journal of Nuclear Medicine (1978), 60, 7, (2019), pp. 1017-1022
Article / Letter to editor
Display more detailsDisplay less details
The Journal of Nuclear Medicine (1978)
SubjectRadboudumc 14: Tumours of the digestive tract RIMLS: Radboud Institute for Molecular Life Sciences; Radboudumc 15: Urological cancers RIHS: Radboud Institute for Health Sciences; Radboudumc 19: Nanomedicine RIMLS: Radboud Institute for Molecular Life Sciences; Radboudumc 9: Rare cancers RIMLS: Radboud Institute for Molecular Life Sciences
The aim was to compare the prostate-specific membrane antigen (PSMA)-targeting characteristics of PSMA-11, radiolabeled on the basis of chelation of (18)F-AlF, with those of (68)Ga-PSMA-11 to image PSMA-expressing xenografts. Methods: Labeling of (18)F-AlF-PSMA-11 via (18)F-AlF-complexation was performed as described by Boschi et al. and Malik et al. with minor modifications. Several conditions for the quality control of the labeling of (18)F-AlF-PSMA-11 via (18)F-AlF-complexation were evaluated to characterize the influence of ethanol, acetonitrile, and trifluoroacetic acid on the stability of the labeled product. Internalization kinetics of (18)F-AlF-PSMA-11 were compared with those of (68)Ga-PSMA-11 using PSMA-expressing LNCaP tumor cells. Biodistribution of (18)F-AlF-PSMA-11 (0.26 nmol/mouse, 8-9 MBq/mouse) in male BALB/c nude mice with PSMA-expressing subcutaneous LS174T-PSMA tumors was compared with that of (68)Ga-PSMA-11 at 1 and 2 h after injection. In addition, (18)F-AlF-PSMA-11 PET/CT and (68)Ga-PSMA-11 PET/CT imaging were performed at 1 and 2 h after injection. Results: In contrast to (68)Ga-PSMA-11, (18)F-AlF-PSMA-11 was not stable in water (radiochemical purity was 64.5% immediately after purification and 52.7% at 120 min after purification). (18)F-AlF-PSMA-11 remained relatively stable in 25 mM NH4OAc, pH 6.9, and radiochemical purity decreased from 98.5% at purification to 96.3%, 94.7%, and 92.5% at 60, 120, and 180 min after purification. In vitro, the (18)F- and (68)Ga-labeled compounds showed rapid internalization in LS174T-PSMA cells. The highest tumor uptake (percentage injected dose [%ID]) was observed at 2 h after injection (10.8 +/- 2.3 %ID/g and 7.9 +/- 1.3 %ID/g for (18)F-AlF-PSMA-11 and (68)Ga-PSMA-11, respectively [P > 0.05]). Renal tracer uptake peaked at 2 h after injection (43.5 +/- 5.7 %ID/g and 105.8 +/- 13.8 %ID/g for (18)F-AlF-PSMA-11 and (68)Ga-PSMA-11, respectively, P < 0.05). Bone uptake of (18)F-AlF-PSMA-11 was 3.3 +/- 0.6 at 1 h after injection and 5.0 +/- 0.6 %ID/g at 2 h after injection and was dependent on the radiochemical purity at the time of injection. Bone uptake of (68)Ga-PSMA-11 reached 0.1 +/- 0.0 %ID/g at 1 and 2 h after injection. PSMA-expressing xenografts could be visualized using both (68)Ga-PSMA-11- and (18)F-AlF-PSMA-11 PET/CT. Conclusion: (18)F-AlF-PSMA-11 using direct labeling with aluminum fluoride can be produced in NH4OAc, pH 6.9; shows a high internalization rate; and visualizes PSMA-expressing tumors with similar tumor uptake. Lower kidney uptake than with (68)Ga-PSMA-11 may be advantageous for tumor detection. However, the limited instability and consequent Al(18)F uptake in bone might hamper the visualization of small PCa bone metastases.
Upload full text
Use your RU credentials (u/z-number and password) tolog in with SURFconextto upload a file for processing by the repository team.